Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection...

Area of Science:

• Microbiome research
• Infectious diseases
• Therapeutic development

Background:

• Recurrent multidrug-resistant (MDR) urinary tract infections (UTIs) pose a significant clinical challenge.
• The gut microbiome's role in infection and disease recurrence is an area of active investigation.
• Microbiome restoration therapeutics aim to re-establish a healthy gut microbial community.

Purpose of the Study:

• To evaluate the efficacy of RBX2660, an investigational microbiome therapeutic, in a patient with recurrent MDR UTI.
• To assess the impact of RBX2660 on gut microbiome diversity and uropathogen carriage.
• To determine if microbiome diversity restoration prevents disease recurrence.

Main Methods:

• Administration of RBX2660, a microbiome restoration therapeutic.
• Monitoring of gut microbiome diversity.
• Assessment of uropathogen carriage and UTI recurrence.
• Subsequent antibiotic exposure was noted.

Main Results:

• RBX2660 administration led to increased gut microbiome diversity.
• Uropathogen carriage was not eliminated by RBX2660 treatment.
• The patient experienced recurrence of MDR UTI following subsequent antibiotic exposure.

Conclusions:

• Restoration of gut microbiome diversity does not guarantee the eradication of uropathogens.
• Increased microbiome diversity alone may not be sufficient to prevent recurrent MDR UTIs.
• Residual MDR pathogens can persist and cause disease recurrence even after microbiome modulation.